MPS 7, MPS VII, Mucopolysaccharidosis VII, Sly Syndrome
Conditions
Keywords
UX003, Mepsevii, vestronidase alfa-vjbk, vestronidase alfa, recombinant human beta-glucuronidase
Brief summary
The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.
Detailed description
The Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP) is a global, prospective, multicenter, longitudinal protocol designed to characterize MPS VII disease presentation and progression, assess long-term effectiveness and safety of vestronidase alfa, including hypersensitivity reactions and immunogenicity , as well as prospectively investigate longitudinal change across biomarker(s), clinical assessments, and patient/ caregiver-reported outcome measures in a representative population. The aim of this DMP is to collect data on patients with MPS VII to provide a comprehensive dataset on the clinical presentation, heterogeneity, and disease progression, and meaningful standardized ICH GCP-quality data collected in-clinic across multiple sites globally. The DMP is not a randomized study and both treated and untreated patients will be enrolled.
Interventions
OTHERNo Intervention
Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
Sponsors
Ultragenyx Pharmaceutical Inc
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Diagnosis of MPS VII based on laboratory diagnosis, including either enzymatic or mutation analysis. * Willing and able to provide written informed consent or, in the case of patients under the age of 18 (or below adult ages as defined by local laws and regulations) or patients \>18 years of age who have cognitive deficiencies, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the DMP has been explained, and prior to any research-related procedures. * Willing to comply with DMP visit schedule.
Exclusion criteria
* Concurrent participation in other pharmaceutical company-sponsored interventional clinical trial unless approved by Ultragenyx.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Long-term Safety of Vestronidase Alfa | 10 years | Hypersensitivity reactions, immunogenicity and other safety outcomes will be assessed to examine the long-term safety of vestronidase alfa. |
| Clinical Course of MPS VII Disease | 10 years | To characterize MPS VII disease presentation and progression over time in patients treated and not treated with vestronidase alfa |
| Long-term Effectiveness of Vestronidase Alfa | 10 years | To evaluate longitudinal change in biomarker(s), clinical assessments and patient/caregiver reported outcomes to examine the effectiveness of vestronidase alfa |
Countries
Argentina, Brazil, France, Germany, Netherlands, Portugal, Spain, United States
Contacts
CONTACTPatients Contact: Trial Recruitment
CONTACTHCPs Contact: Medical Information
STUDY_DIRECTORMedical Director
Ultragenyx Pharmaceuticals Inc.
Outcome results
None listed